RET and breast neoplasm: RET is overexpressed in ∼50% of breast tumors and has been suggested as an alternative therapeutic target, particularly in light of the recent advances in novel RET inhibitors (Belli et al., 2020; Gattelli et al., 2020; Paratala et al., 2018).